Despite the successful application of anti-CD47 and anti-SIRPα blocking antibodies in immunotherapy against cancer cells, the potential of engaging SIRPα to restrain excessive immune activation in the context of ILC2s and allergic lung inflammation remains unexplored. Here, CD47 is linked to cancer.